- Home
- APLT vs CHMI Comparison
APLT vs CHMI Comparison
Compare APLT & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CHMI
- Stock Information
- Founded
- APLT 2016
- CHMI 2012
- Country
- APLT United States
- CHMI United States
- Employees
- APLT N/A
- CHMI N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CHMI Real Estate Investment Trusts
- Sector
- APLT Health Care
- CHMI Real Estate
- Exchange
- APLT Nasdaq
- CHMI Nasdaq
- Market Cap
- APLT 80.3M
- CHMI 92.0M
- IPO Year
- APLT 2019
- CHMI 2013
- Fundamental
- Price
- APLT $0.52
- CHMI $3.44
- Analyst Decision
- APLT Buy
- CHMI Buy
- Analyst Count
- APLT 7
- CHMI 3
- Target Price
- APLT $6.10
- CHMI $5.00
- AVG Volume (30 Days)
- APLT 1.6M
- CHMI 331.2K
- Earning Date
- APLT 05-08-2025
- CHMI 03-06-2025
- Dividend Yield
- APLT N/A
- CHMI 17.37%
- EPS Growth
- APLT N/A
- CHMI N/A
- EPS
- APLT N/A
- CHMI 0.07
- Revenue
- APLT N/A
- CHMI $46,993,000.00
- Revenue This Year
- APLT N/A
- CHMI $14.91
- Revenue Next Year
- APLT $2,426.33
- CHMI N/A
- P/E Ratio
- APLT N/A
- CHMI $50.58
- Revenue Growth
- APLT N/A
- CHMI N/A
- 52 Week Low
- APLT $0.43
- CHMI $2.50
- 52 Week High
- APLT $10.62
- CHMI $3.99
- Technical
- Relative Strength Index (RSI)
- APLT 43.47
- CHMI 44.71
- Support Level
- APLT $0.52
- CHMI $3.54
- Resistance Level
- APLT $0.62
- CHMI $3.67
- Average True Range (ATR)
- APLT 0.05
- CHMI 0.10
- MACD
- APLT 0.01
- CHMI -0.02
- Stochastic Oscillator
- APLT 23.19
- CHMI 30.30
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.